AstraZeneca's Imfinzi, or durvalumab, received orphan drug designation from the FDA to treat small cell lung cancer. The drug resulted in statistically significant improvements in this patient population's overall survival.
FDA grants orphan drug designation to AstraZeneca's durvalumab
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.